PTC Therapeutics Enters Material Definitive Agreement
Ticker: PTCT · Form: 8-K · Filed: Jan 3, 2025 · CIK: 1070081
Sentiment: neutral
Topics: material-definitive-agreement, financial-obligation, pharmaceuticals
Related Tickers: PTCT
TL;DR
PTC THERAPEUTICS (PTCT) just signed a big deal, expect financial moves.
AI Summary
On December 31, 2024, PTC Therapeutics, Inc. entered into a material definitive agreement, creating a direct financial obligation. The company, headquartered in Warren, NJ, is involved in the pharmaceutical preparations industry.
Why It Matters
This filing indicates a significant new financial commitment or obligation for PTC Therapeutics, which could impact its financial standing and future operations.
Risk Assessment
Risk Level: medium — Entering into material definitive agreements can introduce new financial obligations or strategic shifts that carry inherent risks.
Key Numbers
- 001-35969 — SEC File Number (Identifies the company's filing with the SEC)
- 04-3416587 — IRS Employer Identification No. (Company's tax identification number)
Key Players & Entities
- PTC Therapeutics, Inc. (company) — Filer of the 8-K report
- December 31, 2024 (date) — Date of the earliest event reported
- 500 Warren Corporate Center Drive, Warren, NJ 07059 (location) — Company's business and mail address
FAQ
What type of material definitive agreement did PTC Therapeutics enter into?
The filing states that PTC Therapeutics, Inc. entered into a material definitive agreement on December 31, 2024, which resulted in a direct financial obligation or an obligation under an off-balance sheet arrangement.
What is the primary business of PTC Therapeutics, Inc.?
PTC Therapeutics, Inc. is classified under the Standard Industrial Classification code 2834, which pertains to Pharmaceutical Preparations.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on December 31, 2024.
Where is PTC Therapeutics, Inc. headquartered?
PTC Therapeutics, Inc.'s business and mail address is located at 500 Warren Corporate Center Drive, Warren, NJ 07059.
What is the SEC file number for PTC Therapeutics, Inc.?
The SEC file number for PTC Therapeutics, Inc. is 001-35969.
Filing Stats: 824 words · 3 min read · ~3 pages · Grade level 11.3 · Accepted 2025-01-03 16:27:37
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share PTCT Nasdaq Glo
- $57.7 m — ll pay a reduced aggregate base rent of $57.7 million, reflecting a reduction of $57.7
- $57.7 million — 57.7 million, reflecting a reduction of $57.7 million to the aggregate base rent for the init
- $36.1 million — vements to the Premises is reduced from $36.1 million to $23.9 million, which is to be paid i
- $23.9 m — emises is reduced from $36.1 million to $23.9 million, which is to be paid in accordanc
- $8.1 million — Credit") in the amount of approximately $8.1 million for a term of not less than the earlier
- $10.0 million — e the amount of the security deposit to $10.0 million (the "Amended Letter of Credit"). If af
- $5.0 million — ded Letter of Credit will be reduced to $5.0 million. If after December 31, 2028, the Compan
- $2.5 million — er of Credit will be further reduced to $2.5 million. The foregoing summaries of the Amendm
Filing Documents
- tmb-20241231x8k.htm (8-K) — 42KB
- 0001070081-25-000004.txt ( ) — 162KB
- tmb-20241231.xsd (EX-101.SCH) — 4KB
- tmb-20241231_def.xml (EX-101.DEF) — 3KB
- tmb-20241231_lab.xml (EX-101.LAB) — 16KB
- tmb-20241231_pre.xml (EX-101.PRE) — 9KB
- tmb-20241231x8k_htm.xml (XML) — 5KB
01. Entry Into a Material Definitive Agreement
Item 1.01. Entry Into a Material Definitive Agreement. On December 31, 2024, PTC Therapeutics, Inc. (the "Company") and Warren CC Acquisitions, LLC, (the "Landlord") entered into a First Amendment to Lease Agreement (the "Amendment"), which amends that certain Lease Agreement dated as of May 24, 2022 between the Company and the Landlord (the "Lease Agreement"). The Lease Agreement was initially for two entire buildings comprised of approximately 360,000 square feet of shell condition, modifiable space (the "Premises") at a facility located in Warren, New Jersey over an initial term of 17 years. Pursuant to the Amendment, as of the Surrender Effective Date (as defined in the Amendment), the Company will only be leasing one building comprised of approximately 180,000 square feet. The Company will continue paying rent as scheduled, along with certain maintenance and utilities costs, through the end of December 2027, after which the Company will pay a reduced aggregate base rent of $57.7 million, reflecting a reduction of $57.7 million to the aggregate base rent for the initial Term (as defined in the Lease Agreement). Under the Amendment, the Company's allowance provided by the Landlord to be used towards certain improvements to the Premises is reduced from $36.1 million to $23.9 million, which is to be paid in accordance with the Lease Agreement. Under the Lease Agreement, the Company was also obligated to provide the Landlord with an unconditional evergreen letter of credit (the "Letter of Credit") in the amount of approximately $8.1 million for a term of not less than the earlier of (i) three years or (ii) sixty days after the Expiration Date (as defined in the Lease Agreement), as a security deposit. Under the Amendment, the Letter of Credit shall be amended to increase the amount of the security deposit to $10.0 million (the "Amended Letter of Credit"). If after July 1, 2027, the Company is not in default of the Lease Agreement and meets certain creditworthin